Usher Syndrome Market

Market Overview:

The 7 major Usher syndrome markets reached a value of US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1.7 Billion by 2034, exhibiting a growth rate (CAGR) of 3.61% during 2024-2034.

The Usher syndrome market has been comprehensively analyzed in IMARC's new report titled "Usher Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Usher syndrome refers to a rare genetic disorder characterized by a combination of hearing loss or deafness and progressive vision loss. This condition primarily affects the inner ear, leading to varying degrees of hearing impairment, and also involves the gradual deterioration of vision due to retinitis pigmentosa, a degenerative eye disorder. The symptoms of the ailment can differ widely among patients and can occur during infancy or adulthood. Hearing loss or deafness is often present from birth or early childhood, and it can range from mild to profound. The vision loss associated with retinitis pigmentosa typically emerges later in childhood or adolescence, causing night blindness and a narrowing field of vision, ultimately leading to tunnel vision or complete blindness over time. The diagnosis of Usher syndrome involves comprehensive medical and genetic assessments. Audiological tests can determine the extent of hearing loss, while visual field tests and retinal imaging can help to identify retinitis pigmentosa.

The escalating prevalence of mutations in genes, such as MYO7A, USH1C, and CDH23, which are integral to the proper functioning of the auditory and visual systems, is primarily driving the Usher syndrome market. In addition to this, the inflating utilization of efficient therapeutic solutions, including cochlear implants for hearing loss and retinal implants for visual impairments, is also creating a positive outlook for the market. Moreover, the widespread adoption of audiological and ophthalmological rehabilitation techniques, since they help to improve the independence and quality of life for individuals suffering from the illness, is further bolstering the market growth. Apart from this, the growing research and development activities that are poised to uncover novel treatment modalities and medications, which can alleviate or even reverse the symptoms of Usher syndrome are acting as another significant growth-inducing factor. Additionally, the emerging popularity of antioxidant supplements, such as vitamin A and vitamin E, to slow down disease progression is also augmenting the market growth. Furthermore, the escalating application of gene therapy, since it involves delivering corrective genetic material to cells, thereby rectifying or replacing the faulty genes responsible for the disorder, is expected to drive the Usher syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Usher syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Usher syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Usher syndrome market in any manner.

Recent Developments:

• In December 2023, ProQR Therapeutics N.V. stated that it had divested its late-stage ophthalmology assets, sepofarsen and ultevursen, to Laboratoires Théa.

Key Highlights

• Usher syndrome is a rare condition in the general population, with an incidence of three instances per 100,000 people.
• Usher syndrome is substantially more common in the genetically deaf, accounting for 5-10% of persons with the impairment.
• In the United States, it affects around one in every 23,000 persons.
• Usher syndrome is categorized into three major subtypes: I, II, and III.
• Type I Usher Syndrome is more common in people of Ashkenazi Jewish or French Acadian origin.
• Type III represents just approximately 2% of all cases.

Drugs:

NT-501 is under development by Neurotech Pharmaceuticals for the treatment of Usher syndrome. NT-501 is an intraocular implant, which is made up of encapsulated human cells that have been genetically engineered (identified as NTC-201) to produce ciliary neurotrophic factor (CNTF). It is intended to continuously provide a low, safe, and therapeutic amount of CNTF into the back of the eye.

Ultevursen (previously QR-421a) is a first-in-class experimental RNA treatment that aims to treat the fundamental cause of vision loss in Usher syndrome type 2a and non-syndromic retinitis pigmentosa owing to mutations in exon 13 of the USH2A gene. QR-421a is meant to restore functional usherin protein utilizing an exon skipping technique, with the objective of stopping or reversing eyesight loss in patients.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Usher syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Usher syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current usher syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Usher syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Usher syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Usher syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Usher syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Usher syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Usher syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Usher syndrome across the seven major markets?
• What is the size of the Usher syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Usher syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Usher Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Usher syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Usher syndrome market?
• What are the key regulatory events related to the Usher syndrome market?
• What is the structure of clinical trial landscape by status related to the Usher syndrome market?
• What is the structure of clinical trial landscape by phase related to the Usher syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Usher syndrome market?